{{subs:submit}}

Dr. Maria R. Baer 

Maria R. Baer is a Medical Doctor who specializes in Leukemia, drug resistance, and cell signaling. Her research has made strides in fighting many types of cancer. Her research has helped fight cancers that rapidly develop and cancers that have high resurfacing records. Additionally she worked to create ways to fight drug resistant types of cancer. She's been the head of many oncology centers and departments

Biography

Maria R. Baer graduated with a B.A. from Harvard then went to John’s Hopkins Medical School. After her training at Vanderbilt with a fellowship in hematology, she became the chef of Leukemia at Rockwell park cancer institute.[1]  She then went on to become an associate professor at university of buffalo a university which specializes in oncology and hematology illnesses.[2] In a phase 3 clinical trial for a drug concerning acute myeloid leukemia patients, she acted as the principal investigator. Additionally she is a member of many cancer research societies including CALGB/Alliance for Clinical Trials in Oncology Leukemia and Stand Up to Cancer Epigenetics Dream Team. The National Cancer Institute, the Leukemia and Lymphoma Society Translational Research Program and the Department of Veterans Affairs has funded her work on Leukemia. Today she works at University of Maryland as Director, Hematologic Malignancies and Co-Leader, Experimental Therapeutics Program.[1] 

Research

Most of Maria R. Baer's research pertains to drug resistant and cell signaling cancer. For example in a recent publication to fight, Acute Myeloid Leukemia, a certain type of Leukemia that has a nasty tendency to resurface in patients or initially spread with extreme speed. Acute Myeloid Leukemia is a complex cancer due to the fact that it's a cancer of the blood which can start anywhere in the body and can easily spend to organs.[3] To combate this cancer's replication speed Dr.Baer took the replication inhibitors from the cells in the mouth of the patient and inserted them into the cancer reducing its multiplication. This process is preferable to chemotherapy which has nasty side effects.[4]

  1. ^ a b "University of Maryland School of Medicine". www.medschool.umaryland.edu. Retrieved 2017-10-10.
  2. ^ "Jacobs School of Medicine and Biomedical Sciences - University at Buffalo". medicine.buffalo.edu. Retrieved 2017-10-10.
  3. ^ "American Cancer Society | Information and Resources about for Cancer: Breast, Colon, Lung, Prostate, Skin". www.cancer.org. Retrieved 2017-10-10.
  4. ^ "American Cancer Society | Information and Resources about for Cancer: Breast, Colon, Lung, Prostate, Skin". www.cancer.org. Retrieved 2017-10-10.